Docetaxel, Carboplatin and Radiation Followed by Surgical Resection of Patients with State IIIA and B Non-Small Cell Lung Cancer

Grants and Contracts Details

StatusFinished
Effective start/end date8/1/014/30/04

Funding

  • Aventis Pharmaceuticals Products Inc: $15,211.00